Eli Lilly weight-loss pill wins EU backing
The European Medicines Agency has recommended approval for Eli Lilly's oral weight-loss drug Foundayo. The pill targets obesity and type 2 diabetes, following rival Novo Nordisk's treatment in seeking EU market access.
Xurve View
Insights:
Xurve View
ELI LILLY & CO's weight-loss pill Foundayo won European Medicines Agency committee backing on Friday afternoon for weight management and type 2 diabetes. The recommendation makes it the second oral obesity drug to clear the hurdle after NOVO NORDISK A/S-B's rival treatment. Both drugmakers are competing to capture a market projected to surpass $100 billion by 2030.
